Arcoma AB

Stockholm Stock Exchange ARCOMA.ST

Arcoma AB Capital Expenditure for the year ending December 31, 2023: USD -251.98 K

Arcoma AB Capital Expenditure is USD -251.98 K for the year ending December 31, 2023, a 36.71% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Arcoma AB Capital Expenditure for the year ending December 31, 2022 was USD -398.14 K, a 13.65% change year over year.
Arcoma AB Capital Expenditure for the year ending December 31, 2021 was USD -461.10 K, a 67.49% change year over year.
Arcoma AB Capital Expenditure for the year ending December 31, 2020 was USD -1.42 M, a -19.78% change year over year.
Arcoma AB Capital Expenditure for the year ending December 31, 2019 was USD -1.18 M, a -1,048.98% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Stockholm Stock Exchange: ARCOMA.ST

Arcoma AB

CEO	Mr. Mattias Leire
IPO Date	Nov. 14, 2014
Location	Sweden
Headquarters	AnnavAegen 1
Employees	32
Sector	Health Care
Industries Medical Instruments Pharmaceuticals

Description

Arcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners. Arcoma AB was founded in 1990 and is based in Växjö, Sweden.

Key trends

Past 5 years